Treerita Essalima Johnson-Greene bought OCGN once, on Jun 15, 2026

Treerita Essalima Johnson-Greene is a corporate executive and Chief Financial Officer of Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on gene therapies for blindness-related diseases.( As CFO and principal financial officer, she oversees Ocugen’s financial strategy and operations and is also an active corporate insider, recently purchasing 21,000 shares of Ocugen common stock in an open‑market transaction, increasing her direct holdings to 521,000 shares, with additional indirect ownership through her spouse.(

Johnson-Greene brings more than 20 years of healthcare and gene therapy industry experience spanning finance, commercial operations, and executive leadership roles.( Before joining Ocugen, she served as Chief Operating Officer at the Alliance for Regenerative Medicine, leading operations, finance, and global expansion initiatives, and previously held senior roles at Genetix Biotherapeutics (formerly bluebird bio), Spark Therapeutics, and AstraZeneca, after beginning her career in strategic consulting at Accenture Strategy.( She holds an MBA in Finance and Strategic Management from the Wharton School of the University of Pennsylvania and a bachelor’s degree in Electrical (or Electrical and Computer) Engineering from Drexel University, and she contributes to the broader community through service on Drexel University’s Biomed Dean’s Executive Advisory Council and the board of directors of GirlTrek.(

Written by Perplexity from public sources.